Drug Trial Radar · NCT03555149
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Last checked: Nov 19, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
96
Actual
Start
Sep 27, 2018
Primary completion
Sep 26, 2022
Study completion Sep 26, 2022
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) that became refractory to first- and second-line standard therapies. Eligible patients will be assigned to one of several treatment arms.
Conditions
- Colorectal Cancer
Interventions
RegorafenibDrug
Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.
AtezolizumabDrug
Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
Imprime PGGDrug
Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.
BevacizumabDrug
Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.
IsatuximabDrug
Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.
SelicrelumabDrug
Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.
IdasanutlinDrug
Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.
AB928Drug
AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
LOAd703Genetic
LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: From randomization until disease progression or loss of clinical benefit (up to 4 years)
Locations
15 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
Yale University
New Haven, Connecticut
Dana Farber Cancer Institute
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Columbia University Medical Center
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Peter MacCallum Cancer Center
North Melbourne, Victoria, Australia
Centre Georges François Leclerc; Pharmacie des Essais Cliniques
Dijon, France
Centre Leon Berard
Lyon, France
Institut Claudius Regaud; Departement Oncologie Medicale
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Seoul National University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Asan Medical Center.
Seoul, South Korea
CHUV; Departement d'Oncologie
Lausanne, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.